亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial

双氯芬酸 医学 耐受性 布洛芬 安慰剂 麻醉 加药 不利影响 养生 安慰剂对照研究 外科 内科学 双盲 药理学 病理 替代医学
作者
R.-L. Dreiser,Marc Marty,Elisabeta Ionescu,M.H. Gold,J H Liu
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
卷期号:41 (09): 375-385 被引量:42
标识
DOI:10.5414/cpp41375
摘要

To assess efficacy and safety of diclofenac-K 12.5 mg tablets in the treatment of acute low back pain (low back pain).A multiple dose, double-blind, double-dummy, randomized, placebo-controlled, parallel group trial compared diclofenac-K (12.5 mg; n = 124) with ibuprofen (200 mg; n = 122) and placebo (n = 126) in patients with moderate-to-severe acute low back pain. The treatment consisted of an initial dose of 2 tablets followed by 1 or 2 tablets every 4-6 hours as needed (maximum 6 tablets/day) for 7 days. The primary efficacy outcome for the initial dose was TOTPAR-3, the summed total pain relief over the first 3 hours. Secondary initial dose outcomes included TOTPAR-6, summed pain intensity differences SPID-3 and SPID-6, time to rescue medication or remedicate, and the End of First Dose global efficacy assessment. The primary efficacy outcome for the flexible multiple dosing regimen was the End of Study global efficacy assessment. Secondary outcomes for multiple dosing included time to rescue medication over the entire study, the End of Day global efficacy assessments (daily over Days 1-7), pain intensity differences on the VAS measured at Visit 2 and 3, and change in Eifel algofunctional index. Safety/tolerability was assessed by recording adverse events.Diclofenac-K 12.5 mg demonstrated superiority vs placebo on the primary efficacy parameter and almost all secondary initial dose outcomes. With respect to the initial dose, diclofenac-K 12.5 mg was also significantly superior to ibuprofen 200 mg on SPID-3. Ibuprofen 200 mg was superior to placebo only on the End of First Dose global efficacy assessment. The flexible multiple dosing regimens of diclofenac-K and ibuprofen were both significantly superior to placebo on the End of Study global efficacy assessment, time to rescue medication over the entire study period, the End of Day global efficacy assessment on Days 1-2, pain intensity difference on the VAS at Visit 3 and the Eifel algofunctional index at Visit 3 (also at Visit 2 in diclofenac-K 12.5 mg group). Both active treatments were as well tolerated as placebo.The flexible multiple dosing regimen of diclofenac-K 12.5 mg (initial dose of 2 tablets followed by 1-2 tablets every 4-6 hours, max. 75 mg/day) is an effective and safe treatment of acute low back pain.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无谓完成签到,获得积分10
刚刚
清脆曼岚完成签到,获得积分10
1秒前
开放的子默完成签到,获得积分10
1秒前
灵巧绿海发布了新的文献求助10
3秒前
香蕉觅云的应助被阿九采纳,获得10
7秒前
8秒前
9秒前
joejoe完成签到,获得积分10
12秒前
13秒前
15秒前
15秒前
chuchu7613完成签到,获得积分20
20秒前
29秒前
阿九完成签到,获得积分10
29秒前
兔鸟完成签到 ,获得积分10
30秒前
32秒前
阿九发布了新的文献求助10
32秒前
灵巧绿海完成签到,获得积分10
33秒前
xixi完成签到 ,获得积分10
35秒前
42秒前
47秒前
大胆醉卉完成签到,获得积分10
48秒前
48秒前
科研通AI6.2的应助被weako采纳,获得30
49秒前
科研通AI6.4的应助被weako采纳,获得30
49秒前
生动琦完成签到,获得积分10
50秒前
生动的电脑完成签到,获得积分10
50秒前
zsp完成签到,获得积分10
52秒前
pcs发布了新的文献求助10
53秒前
昨日晚晴完成签到 ,获得积分10
54秒前
56秒前
感存算完成签到,获得积分10
57秒前
59秒前
fantasy的应助被科研通管家采纳,获得10
59秒前
研友_LwlNdn的应助被科研通管家采纳,获得10
59秒前
隐形曼青的应助被Un1que采纳,获得10
1分钟前
1分钟前
王乐安完成签到,获得积分10
1分钟前
坦率的邑完成签到 ,获得积分10
1分钟前
TFoCR7发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179795
求助须知:如何正确求助?哪些是违规求助? 9570000
关于积分的说明 21808049
捐赠科研通 7775402
什么是DOI,文献DOI怎么找? 3433137
关于科研通互助平台的介绍 2557199
邀请新用户注册赠送积分活动 2478832